Likmez is a drug owned by Saptalis Pharmaceuticals Llc. It is protected by 1 US drug patent filed in 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 04, 2039. Details of Likmez's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11541035 | Oral formulations of metronidazole and methods of treating an infection using same |
Oct, 2039
(14 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Likmez's patents.
Latest Legal Activities on Likmez's Patents
Given below is the list of recent legal activities going on the following patents of Likmez.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 07 May, 2024 | US11541035 |
| Patent eCofC Notification | 07 May, 2024 | US11541035 |
| Recordation of Patent eCertificate of Correction | 07 May, 2024 | US11541035 |
| Mail Patent eCofC Notification | 07 May, 2024 | US11541035 |
| Mail Certificate of Correction Memo | 17 Apr, 2024 | US11541035 |
| Certificate of Correction Memo | 12 Apr, 2024 | US11541035 |
| Recordation of Patent Grant Mailed Critical | 03 Jan, 2023 | US11541035 |
| Patent Issue Date Used in PTA Calculation Critical | 03 Jan, 2023 | US11541035 |
| Email Notification Critical | 15 Dec, 2022 | US11541035 |
| Issue Notification Mailed Critical | 14 Dec, 2022 | US11541035 |
US patents provide insights into the exclusivity only within the United States, but Likmez is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Likmez's family patents as well as insights into ongoing legal events on those patents.
Likmez's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Likmez's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 04, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Likmez Generic API suppliers:
Metronidazole is the generic name for the brand Likmez. 38 different companies have already filed for the generic of Likmez, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Likmez's generic
Alternative Brands for Likmez
Likmez which is used for treating symptoms of anxiety and depression., has several other brand drugs using the same active ingredient (Metronidazole). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Bausch |
| |
| Chemo Research Sl |
| |
| Galderma Labs Lp |
| |
| Labs Juvise |
| |
| Pfizer |
| |
| Teva Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Metronidazole, Likmez's active ingredient. Check the complete list of approved generic manufacturers for Likmez
About Likmez
Likmez is a drug owned by Saptalis Pharmaceuticals Llc. It is used for treating symptoms of anxiety and depression. Likmez uses Metronidazole as an active ingredient. Likmez was launched by Saptalis Pharms in 2023.
Approval Date:
Likmez was approved by FDA for market use on 22 September, 2023.
Active Ingredient:
Likmez uses Metronidazole as the active ingredient. Check out other Drugs and Companies using Metronidazole ingredient
Treatment:
Likmez is used for treating symptoms of anxiety and depression.
Dosage:
Likmez is available in suspension form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 500MG/5ML | SUSPENSION | Prescription | ORAL |